Search
Exenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalBydureon BCise, an auto-injector extended-release formulation, remains available.[L42700] … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.
Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MGArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ARTESUNATE FOR INJECTION, ARTESUN POWDER FOR INJECTION 60 MGLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: PREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML, PREVYMIS 240mg/12mL (20mg/mL) concentrate for solution for infusionMetformin
go.drugbank.com/drugs/DB00331ApprovedInvestigational[A176173] Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. … [L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia.
Products: Mar-metformin, Mar-metformin XRAntihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Mixtures: HAEMATE P, HAEMATE PProducts: ADVATE 250 IU Powder and Solvent for Solution for Injection, ADVATE 500 IU Powder and Solvent for Solution for InjectionEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection an...
Products: ./0.6ML FER, ./0.8ML FEREvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered … candidates for cytotoxic chemotherapy [A98].
Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIALPhenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalAn indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects.
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L44311] Full approval for this indication was granted in June 2023. … Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through
Products: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vial